Vaccines

There's mounting research to suggest that protecting people who are immuno-compromised from getting COVID is important not just for their sake – it could be critical in the effort to end the pandemic for everyone.

The evidence comes from two separate strands of studies.

Dr. Laura McCoy has been doing the first type. She's an infectious disease researcher at University College London.

"The group of people that I'm particularly interested in are those living with HIV," she says.

She's been studying how well their immune systems respond to vaccines against COVID-19 — specifically the Pfizer vaccine.

So far, it's worked quite well for HIV-positive people.

But there's a catch. In her studies, "all of our participants had really quite well-controlled HIV."

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Situation Report

Russia's Sputnik V vaccine only slightly less effective against Delta variant, developers say

Tue, 2021-06-29 12:11 — mike kraft

Russia's Sputnik V shot around 90% effective against Delta variant, developers say Russia's Sputnik V vaccine against COVID-19 is around 90% effective against the highly contagious Delta variant of coronavirus, its developers said on Tuesday. Reuters Staff U.S.

MOSCOW (Reuters) -Russia’s Sputnik V vaccine against COVID-19 is around 90% effective against the highly contagious Delta variant of coronavirus, its developers said on Tuesday.

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Situation Report

Read more about Russia's Sputnik V vaccine only slightly less effective against Delta variant, developers say
Log in or register to post comments

Three studies offered fresh evidence that widely used vaccines will continue to protect people against the coronavirus for long periods

Tue, 2021-06-29 09:36 — mike kraft

Three scientific studies released on Monday offered fresh evidence that widely used vaccines will continue to protect people against the coronavirus for long periods, possibly for years, and can be adapted to fortify the immune system still further if needed.

Most people immunized with the mRNA vaccines may not need boosters, one study found, so long as the virus and its variants do not evolve much beyond their current forms — which is not guaranteed. Mix-and-match vaccination shows promise, a second study found, and booster shots of one widely used vaccine, if they are required, greatly enhance immunity, according to a third report.

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Analysis

Study indicates mix-and-match Covid vaccine approach boosts immune response

Tue, 2021-06-29 09:26 — mike kraft

Mixing different types of Covid vaccines can boost immune response, study finds Some European countries have started offering alternatives to AstraZeneca as a second shot after the vaccine was linked to rare blood clots. NBC News

A mixed schedule of vaccines where a shot of Pfizer's Covid-19 vaccine is given four weeks after an AstraZeneca shot will produce better immune responses than giving another dose of AstraZeneca, an Oxford study said on Monday.

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Analysis

Situation Report

Read more about Study indicates mix-and-match Covid vaccine approach boosts immune response
Log in or register to post comments

Trial of first coronavirus variant vaccine, Oxford/AstraZeneca, under way

Mon, 2021-06-28 19:14 — mike kraft

Covid-19 news: Trial of first coronavirus variant vaccine under way The latest coronavirus news updated every day including coronavirus cases, the latest news, features and interviews from New Scientist and essential information about the covid-19 pandemic Michael Le Page, Clare Wilson, Jessica Hamzelou, Sam Wong, Graham Lawton, Adam Vaughan, Conrad Quilty-Harper and Layal Liverpool New Scientist

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Situation Report

Read more about Trial of first coronavirus variant vaccine, Oxford/AstraZeneca, under way
Log in or register to post comments

Young Adults Are Among the Biggest Barriers to Mass Immunity in the U.S.

Mon, 2021-06-28 18:00 — mike kraft

...

As the country’s vaccination campaign slows and doses go unused, it has suddenly become clear that one of the biggest barriers to mass immunity will be persuading skeptical young adults of all backgrounds to get shots. Federal officials expressed alarm in recent days about low vaccination rates among Americans in their late teens and 20s, and have blamed them for the country’s all-but-certain failure to reach President Biden’s goal of giving 70 percent of adults at least an initial dose by July 4.

Country / Region Tags:

General Topic Tags: